Biotech firm Curis beats Q3 revenue estimates

Reuters11-07

Biotech firm Curis beats Q3 revenue estimates

Overview

Curis Q3 revenue increased year-over-year, beating analysts' expectations of a decline
Net loss for Q3 narrowed to $7.13 mln from $10.1 mln
Company continues advancing clinical studies in PCNSL, CLL, and AML

Outlook

Curis expects to enroll first CLL patient in late Q4 2025 or early Q1 2026
Company anticipates cash runway into Q1 2026

Result Drivers

ROYALTY REVENUE - Revenue rose to $3.2 mln from $2.9 mln, consisting of royalty revenues from Genentech/Roche's sales of Erivedge
R&D EXPENSES - Declined to $6.4 mln from $9.7 mln due to lower clinical, employee related, manufacturing, research, and consulting costs

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Beat	$3.18 mln	$2.86 mln (5 Analysts)
Q3 Net Income	Beat	-$7.73 mln	-$8.22 mln (5 Analysts)
Q3 Basic EPS	Beat	-$0.49	-$0.58 (5 Analysts)
Q3 Income From Operations	Beat	-$6.92 mln	-$8.20 mln (4 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Curis Inc is $17.00, about 91.6% above its November 5 closing price of $1.42

Press Release: ID:nPn2cV58Xa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581010723?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581010723","market":"us","top_or_hot":-1,"title":"Biotech firm Curis beats Q3 revenue estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotech firm Curis beats Q3 revenue estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Curis Q3 revenue increased year-over-year, beating analysts' expectations of a decline</p></li><li><p>Net loss for Q3 narrowed to $7.13 mln from $10.1 mln</p></li><li><p>Company continues advancing clinical studies in PCNSL, CLL, and AML</p></li></ul><p><span>Outlook</span></p><ul><li><p>Curis expects to enroll first CLL patient in late Q4 2025 or early Q1 2026</p></li><li><p>Company anticipates cash runway into Q1 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ROYALTY REVENUE - Revenue rose to $3.2 mln from $2.9 mln, consisting of royalty revenues from Genentech/Roche's sales of Erivedge</p></li><li><p>R&amp;D EXPENSES - Declined to $6.4 mln from $9.7 mln due to lower clinical, employee related, manufacturing, research, and consulting costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Beat</p></td><td><p>$3.18 mln</p></td><td><p>$2.86 mln (5 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$7.73 mln</p></td><td><p>-$8.22 mln (5 Analysts)</p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td><p>Beat</p></td><td><p>-$0.49</p></td><td><p>-$0.58 (5 Analysts)</p></td></tr><tr><td><p>Q3 Income From Operations</p></td><td><p>Beat</p></td><td><p>-$6.92 mln</p></td><td><p>-$8.20 mln (4 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Curis Inc is $17.00, about 91.6% above its November 5 closing price of $1.42</p></li></ul><p>Press Release: <span>ID:nPn2cV58Xa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech firm Curis beats Q3 revenue estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech firm Curis beats Q3 revenue estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotech firm Curis beats Q3 revenue estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Curis Q3 revenue increased year-over-year, beating analysts' expectations of a decline</p></li><li><p>Net loss for Q3 narrowed to $7.13 mln from $10.1 mln</p></li><li><p>Company continues advancing clinical studies in PCNSL, CLL, and AML</p></li></ul><p><span>Outlook</span></p><ul><li><p>Curis expects to enroll first CLL patient in late Q4 2025 or early Q1 2026</p></li><li><p>Company anticipates cash runway into Q1 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ROYALTY REVENUE - Revenue rose to $3.2 mln from $2.9 mln, consisting of royalty revenues from Genentech/Roche's sales of Erivedge</p></li><li><p>R&amp;D EXPENSES - Declined to $6.4 mln from $9.7 mln due to lower clinical, employee related, manufacturing, research, and consulting costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Beat</p></td><td><p>$3.18 mln</p></td><td><p>$2.86 mln (5 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$7.73 mln</p></td><td><p>-$8.22 mln (5 Analysts)</p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td><p>Beat</p></td><td><p>-$0.49</p></td><td><p>-$0.58 (5 Analysts)</p></td></tr><tr><td><p>Q3 Income From Operations</p></td><td><p>Beat</p></td><td><p>-$6.92 mln</p></td><td><p>-$8.20 mln (4 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Curis Inc is $17.00, about 91.6% above its November 5 closing price of $1.42</p></li></ul><p>Press Release: <span>ID:nPn2cV58Xa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRIS","symbol_name":"居里","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1HW:1","article_id":"2581010723","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581010723","pubTimestamp":1762463641,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biotech firm Curis beats Q3 revenue estimatesOverviewCuris Q3 revenue increased year-over-year, beating analysts' expectations of a declineNet loss for Q3 narrowed to $7.13 mln from $10.1 mlnCompany c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRIS":"居里","BK4139":"生物科技"},"translate_title":"生物技术公司Curis第三季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRIS":0.9},"content_text":"Biotech firm Curis beats Q3 revenue estimatesOverviewCuris Q3 revenue increased year-over-year, beating analysts' expectations of a declineNet loss for Q3 narrowed to $7.13 mln from $10.1 mlnCompany continues advancing clinical studies in PCNSL, CLL, and AMLOutlookCuris expects to enroll first CLL patient in late Q4 2025 or early Q1 2026Company anticipates cash runway into Q1 2026Result DriversROYALTY REVENUE - Revenue rose to $3.2 mln from $2.9 mln, consisting of royalty revenues from Genentech/Roche's sales of ErivedgeR&D EXPENSES - Declined to $6.4 mln from $9.7 mln due to lower clinical, employee related, manufacturing, research, and consulting costsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueBeat$3.18 mln$2.86 mln (5 Analysts)Q3 Net IncomeBeat-$7.73 mln-$8.22 mln (5 Analysts)Q3 Basic EPSBeat-$0.49-$0.58 (5 Analysts)Q3 Income From OperationsBeat-$6.92 mln-$8.20 mln (4 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Curis Inc is $17.00, about 91.6% above its November 5 closing price of $1.42Press Release: ID:nPn2cV58XaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581010723","isCrawlerRequest":true}